Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2005

View Archived Issues

PDE3/4 inhibitors activate CFTR in a cell culture model

PEP-005 IV shows efficacy in mouse model of acute myeloid leukemia

Phase II data on tadalafil in the treatment of BPH

VRC begins phase II testing of HIV vaccine developed with GenVec

CepTor plans IND for Myodur, seeks orphan drug designation

Phase I study for Fx-1006A to stabilize protein misfolding in hereditary amyloid disorders

Locus establishes Oncology Advisory Board

Enrollment completed in ORIENT studies of olmesartan in diabetic nephropathy

Updated HIV/AIDS treatment guidelines support Fuzeon + PI use

European orphan drug status recommended for tilarginine acetate injection

MM-093 studied in phase IIa trial for psoriasis

Speedel begins clinical testing of new renin inhibitor SPP-635

Altana presents pipeline overview

Exubera recommended for approval in Europe

Alteplase receives new approval in Japan

Recent patents cover therapeutic agents for neurological disorders

Novel agents imparted for the treatment of autoimmune and inflammatory disorders

Treatments for cancer in early development

New data on the antifungal effects of R-126638

Licochalcone A-based skin care products reduce erythema in rosacea

Phase III data on the therapeutic benefits of BG-00012 in psoriasis

CNTO-1275 improves symptoms, quality of life of patients with moderate to severe psoriasis

Granisetron shows promise in the treatment of rosacea

Results with rifaximin encouraging in Crohn's disease study

Balsalazide reduces proctosigmoiditis in radiotherapy-treated prostate cancer patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...